Amicus Therapeutics (FOLD) 10-Q2011 Q1 Quarterly report

Filed: 5 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: aforementioned, applied, apply, appointed, appointment, April, area, assign, BESP, central, Chairman, commensurate, competitor, concept, couple, de, deliverable, delivered, discounted, discretion, disruption, documentation, enhanced, enhancement, enterprise, Europe, expertise, expired, field, iii, influence, interchangeable, knowledge, largely, launch, leader, matthew, meet, modification, NDA, neurodegeneration, partnership, past, pattern, patterson, permanent, premium, President, proof, rare, receipt, remeasure, resignation, resigned, responsibility, role, shortly, similarly, situated, standalone, strength, substantive, TPE, transfer, transition, undelivered, underway, validating, vendor, VSOE, week

Removed: accumulation, ADDF, assessed, automatically, awarded, began, behavioral, brain, category, circulation, closed, combination, comparing, comply, contractually, converted, creating, dated, decreased, deferred, demand, Dentzer, designed, disaggregation, divided, division, efficacy, enable, European, execute, federal, filtration, final, forefront, Foundation, full, Gaucher, GCase, GFR, glomerular, goal, half, HCl, implemented, improved, improvement, initially, initiation, installment, investigational, Ireland, isofagomine, January, leading, line, location, lower, marketed, Medicare, motor, Mount, mouse, mutually, operational, original, Pompe, preliminary, premier, prevented, prior, priority, prolonged, promising, prospectively, purpose, randomized, reacquired, reduced, relieved, renal, resulted, retained, revised, separation, settlement, shared, show, statutory, straight, substrate, successive, tartrate, terminate, thereunder, underwriting, Union, vest, vested, withholding

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

FOLD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND
PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Amicus Therapeutics, Inc. (the “Company”), that, to his knowledge, the Quarterly Report of the Company on Form 10-Q for the period ended March 31, 2011, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company. This written statement is being furnished to the Securities and Exchange Commission as an exhibit to such Form 10-Q. A signed original of this statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


Date: May 4, 2011	By:	/s/ Matthew R. Patterson
		Matthew R. Patterson
		President and Acting Chief Executive Officer

Date: May 4, 2011	By:	/s/ Daphne Quimi
		Daphne Quimi
		Corporate Controller